When Johnson & Johnson (NYSE: JNJ) reported its most recent quarterly results before the markets opened on Tuesday, the pharmaceutical giant said it had $2.58 in earnings per share (EPS) and $20.6 billion in revenue for its second quarter. The consensus estimates had called for $2.46 in EPS and $20.29 billion in revenue. In the same period of last year, it posted EPS of $2.10 on $20.83 billion in revenue.
Consumer worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 2.3% year over year to $3.54 billion. This was driven by beauty products and over-the-counter products, including upper respiratory and analgesic products.
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 4.4% to $10.53 billion.
Worldwide Medical Devices operational sales, excluding the net impact of acquisitions and divestitures, grew 3.2% to $6.49 billion. This was driven by the growth of electrophysiology products in the Interventional Solutions business, endocutters and international energy products in the Advanced Surgery business.
Alex Gorsky, board chair and chief executive, commented:
We delivered solid second-quarter underlying sales growth and strong earnings growth that enables us to make investments in innovation to accelerate performance in each of our businesses. Our pipelines continue to progress with the launch of new products and several regulatory submissions and approvals, which positions us well to deliver the next wave of transformational products and solutions. I am proud of our talented colleagues across Johnson & Johnson who continue to deliver significant healthcare advances to improve the lives of patients and consumers around the world.
Shares of Johnson & Johnson traded down 1.5% to $132.58 Tuesday morning, in a 52-week range of $121.00 to $148.99. The consensus price target is $149.17.
24/7 Wall St.Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
